Interpace Diagnostics Group, Inc. As a subsidiary of Interpace Biosciences, Interpace Diagnostics offers a range of evidence-based, clinically beneficial molecular diagnostic tests and pathology services. Their cutting-edge genetic and mutational analysis helps to risk-stratify patient samples for various cancers, including thyroid, pancreatic, and lung cancer, enabling healthcare providers to make informed treatment decisions.

Interpace Diagnostics is dedicated to assisting healthcare providers in the diagnosis, triage, and treatment of patients through advanced diagnostics. Their molecular diagnostic tests are supported by rigorous science and allow healthcare providers to avoid unnecessary surgeries while accurately assessing the risk of cancer progression in their patients. With strong research collaborations in oncology and partnerships with major cancer centers, Interpace Biosciences leverages its extensive knowledge and testing capabilities to develop and validate proprietary tests tailored to specific needs and specifications.

Their state-of-the-art, CLIA-certified laboratory ensures accurate results. In the era of high healthcare costs, Interpace Diagnostics aims to optimize patient value by reducing unnecessary surgeries and ensuring appropriate monitoring. Their molecular diagnostic tests provide unparalleled accuracy and clarity, improving outcomes for patients facing a cancer diagnosis.

Interpace Diagnostics currently offers five commercialized molecular diagnostic tests in the marketplace, including PancraGEN®, ThyGeNEXT®, ThyraMIR®, RespriDX™, and BarreGen®. Their experienced team of pathologists and Ph. D.

's provides professional support to customers. By advancing personalized medicine and embracing cutting-edge technology, Interpace Diagnostics is transforming the field of molecular diagnostics